Infectious virion capture by HIV-1 gp120-specific IgG from RV144 vaccinees

scientific article published on 08 May 2013

Infectious virion capture by HIV-1 gp120-specific IgG from RV144 vaccinees is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1128/JVI.02737-12
P932PMC publication ID3700223
P698PubMed publication ID23658446
P5875ResearchGate publication ID236666489

P50authorBarton HaynesQ4865631
Georgia D. TomarasQ63663866
M Anthony MoodyQ73297881
Christina OchsenbauerQ86991008
Peter B GilbertQ88492829
Hua-Xin LiaoQ88608388
Victoria R PolonisQ89151700
Supachai Rerks-NgarmQ89154809
Munir AlamQ89520930
Nicole YatesQ90167585
Punnee PitisuttithumQ92117748
John C KappesQ92482518
Sorachai NitayaphanQ96104415
Pinghuang LiuQ114519513
R Glenn OvermanQ114780420
Jaranit KaewkungwalQ37375750
Thomas DennyQ42939171
Nelson MichaelQ48165776
Guido FerrariQ56481169
Mattia BonsignoriQ56808332
Jerome H KimQ56871312
Youyi FongQ57564569
David C. MontefioriQ63302725
P2093author name stringXiaoying Shen
P2860cites workHIV-1 envelope protein binds to and signals through integrin α4β7, the gut mucosal homing receptor for peripheral T cellsQ22251066
Polyclonal B cell responses to conserved neutralization epitopes in a subset of HIV-1-infected individualsQ24635002
Rapid cloning of high-affinity human monoclonal antibodies against influenza virusQ24644672
Natural antibody and complement mediate neutralization of influenza virus in the absence of prior immunityQ24672388
Vaccine Induction of Antibodies against a Structurally Heterogeneous Site of Immune Pressure within HIV-1 Envelope Protein Variable Regions 1 and 2Q27675879
High-throughput quantitative analysis of HIV-1 and SIV-specific ADCC-mediating antibody responsesQ28242631
H3N2 influenza infection elicits more cross-reactive and less clonally expanded anti-hemagglutinin antibodies than influenza vaccinationQ28743596
Human Immunodeficiency Virus Type 1 Subtype B Ancestral Envelope Protein Is Functional and Elicits Neutralizing Antibodies in Rabbits Similar to Those Elicited by a Circulating Subtype B EnvelopeQ29307502
Antibody neutralization and escape by HIV-1Q29547345
Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine targetQ29547347
Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in ThailandQ29547531
Immune-correlates analysis of an HIV-1 vaccine efficacy trialQ29617377
Rapid evolution of the neutralizing antibody response to HIV type 1 infectionQ29618603
Human immunodeficiency virus type 1 env clones from acute and early subtype B infections for standardized assessments of vaccine-elicited neutralizing antibodiesQ29619015
Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infectionQ29619510
Cross-clade neutralization patterns among HIV-1 strains from the six major clades of the pandemic evaluated and compared in two different models.Q30369026
Human immunodeficiency virus type 1 is trapped by acidic but not by neutralized human cervicovaginal mucusQ30491417
Human cervicovaginal mucus contains an activity that hinders HIV-1 movement.Q30542085
International network for comparison of HIV neutralization assays: the NeutNet reportQ33410826
HIV-1 gp41-specific monoclonal mucosal IgAs derived from highly exposed but IgG-seronegative individuals block HIV-1 epithelial transcytosis and neutralize CD4(+) cell infection: an IgA gene and functional analysisQ33479955
Tiered categorization of a diverse panel of HIV-1 Env pseudoviruses for assessment of neutralizing antibodiesQ33614365
In-solution virus capture assay helps deconstruct heterogeneous antibody recognition of human immunodeficiency virus type 1Q33725718
Prolonged exposure of the HIV-1 gp41 membrane proximal region with L669S substitutionQ33778466
Mapping of epitopes exposed on intact human immunodeficiency virus type 1 (HIV-1) virions: a new strategy for studying the immunologic relatedness of HIV-1.Q33785510
Phenotypic and functional profile of HIV-inhibitory CD8 T cells elicited by natural infection and heterologous prime/boost vaccinationQ33826974
Isolation of a monoclonal antibody that targets the alpha-2 helix of gp120 and represents the initial autologous neutralizing-antibody response in an HIV-1 subtype C-infected individualQ33912373
International Technology Transfer of a GCLP-Compliant HIV-1 Neutralizing Antibody Assay for Human Clinical TrialsQ34150070
Replication competent molecular clones of HIV-1 expressing Renilla luciferase facilitate the analysis of antibody inhibition in PBMCQ34357068
Critical issues in mucosal immunity for HIV-1 vaccine developmentQ34459985
Limited or no protection by weakly or nonneutralizing antibodies against vaginal SHIV challenge of macaques compared with a strongly neutralizing antibodyQ34630446
Initial B-cell responses to transmitted human immunodeficiency virus type 1: virion-binding immunoglobulin M (IgM) and IgG antibodies followed by plasma anti-gp41 antibodies with ineffective control of initial viremiaQ34848486
In vivo gp41 antibodies targeting the 2F5 monoclonal antibody epitope mediate human immunodeficiency virus type 1 neutralization breadthQ34937404
The neutralization breadth of HIV-1 develops incrementally over four years and is associated with CD4+ T cell decline and high viral load during acute infectionQ35076717
Dynamic antibody specificities and virion concentrations in circulating immune complexes in acute to chronic HIV-1 infectionQ35363127
Analysis of a clonal lineage of HIV-1 envelope V2/V3 conformational epitope-specific broadly neutralizing antibodies and their inferred unmutated common ancestorsQ35382871
Generation of transmitted/founder HIV-1 infectious molecular clones and characterization of their replication capacity in CD4 T lymphocytes and monocyte-derived macrophagesQ35826158
Magnitude and breadth of the neutralizing antibody response in the RV144 and Vax003 HIV-1 vaccine efficacy trialsQ36083337
Initial HIV-1 antigen-specific CD8+ T cells in acute HIV-1 infection inhibit transmitted/founder virus replicationQ36086631
Antibody-dependent cellular cytotoxicity-mediating antibodies from an HIV-1 vaccine efficacy trial target multiple epitopes and preferentially use the VH1 gene familyQ36363231
HIV-1 gp41 envelope IgA is frequently elicited after transmission but has an initial short response half-life.Q36874604
Factors associated with the development of cross-reactive neutralizing antibodies during human immunodeficiency virus type 1 infectionQ37033294
GP41-specific antibody blocks cell-free HIV type 1 transcytosis through human rectal mucosa and model colonic epithelium.Q37063527
Recent advances in the characterization of HIV-1 neutralization assays for standardized evaluation of the antibody response to infection and vaccinationQ37119451
Utilization of immunoglobulin G Fc receptors by human immunodeficiency virus type 1: a specific role for antibodies against the membrane-proximal external region of gp41.Q37256661
Genetic variants of HIV-1 in ThailandQ39234678
Heterogeneity of envelope molecules expressed on primary human immunodeficiency virus type 1 particles as probed by the binding of neutralizing and nonneutralizing antibodiesQ39698363
Nonneutralizing antibodies are able to inhibit human immunodeficiency virus type 1 replication in macrophages and immature dendritic cellsQ40274328
Specific Antibody Responses to Vaccination with Bivalent CM235/SF2 gp120: Detection of Homologous and Heterologous Neutralizing Antibody to Subtype E (CRF01.AE) HIV Type 1Q40621694
Heterogeneous neutralizing antibody and antibody-dependent cell cytotoxicity responses in HIV-1 elite controllersQ40659603
Broadly Reactive Antibody-Dependent Cellular Cytotoxic Response to HIV-1 Envelope Glycoproteins Precedes Broad Neutralizing Response in Human InfectionQ41706173
Development of bivalent (B/E) vaccines able to neutralize CCR5-dependent viruses from the United States and ThailandQ41709217
High-throughput isolation of immunoglobulin genes from single human B cells and expression as monoclonal antibodiesQ42939116
Recombinant gp120 vaccine-induced antibodies inhibit clinical strains of HIV-1 in the presence of Fc receptor-bearing effector cells and correlate inversely with HIV infection rateQ46775963
Native HIV type 1 virion surface structures: relationships between antibody binding and neutralization or lessons from the viral capture assayQ47444177
Durable HIV-1 antibody and T-cell responses elicited by an adjuvanted multi-protein recombinant vaccine in uninfected human volunteersQ48036553
Intracellular Neutralization of HIV Transcytosis across Tight Epithelial Barriers by Anti-HIV Envelope Protein dIgA or IgMQ59705753
P433issue14
P407language of work or nameEnglishQ1860
P921main subjectvirionQ1757347
P304page(s)7828-7836
P577publication date2013-05-08
P1433published inJournal of VirologyQ1251128
P1476titleInfectious virion capture by HIV-1 gp120-specific IgG from RV144 vaccinees
P478volume87

Reverse relations

cites work (P2860)
Q41424896A Plant-Derived Multi-HIV Antigen Induces Broad Immune Responses in Orally Immunized Mice
Q35706462A broad range of mutations in HIV-1 neutralizing human monoclonal antibodies specific for V2, V3, and the CD4 binding site
Q33742529Advancing Toward HIV-1 Vaccine Efficacy through the Intersections of Immune Correlates
Q30428633Aggregate complexes of HIV-1 induced by multimeric antibodies
Q34057942Analysis of HLA A*02 association with vaccine efficacy in the RV144 HIV-1 vaccine trial
Q34480617Antibody persistence and T-cell balance: two key factors confronting HIV vaccine development
Q37547245Antigenic properties of the HIV envelope on virions in solution
Q27320687Antigenic properties of the human immunodeficiency virus envelope glycoprotein gp120 on virions bound to target cells
Q37714023Capacity for infectious HIV-1 virion capture differs by envelope antibody specificity
Q34146374Characterization of a monoclonal antibody to a novel glycan-dependent epitope in the V1/V2 domain of the HIV-1 envelope protein, gp120.
Q39108779Complex immune correlates of protection in HIV-1 vaccine efficacy trials
Q37245752Enhanced binding of antibodies generated during chronic HIV infection to mucus component MUC16
Q38210557HIV vaccines: a brief overview.
Q35728947HIV-1 VACCINES. Diversion of HIV-1 vaccine-induced immunity by gp41-microbiota cross-reactive antibodies
Q33939974HIV-1 specific IgA detected in vaginal secretions of HIV uninfected women participating in a microbicide trial in Southern Africa are primarily directed toward gp120 and gp140 specificities
Q33900395HIV-1 vaccine-induced C1 and V2 Env-specific antibodies synergize for increased antiviral activities
Q33577972HIV-1 vaccines: challenges and new perspectives
Q59354714HIV/AIDS Vaccines: 2018
Q27318508Human Non-neutralizing HIV-1 Envelope Monoclonal Antibodies Limit the Number of Founder Viruses during SHIV Mucosal Infection in Rhesus Macaques
Q39108760Immunologic characteristics of HIV-infected individuals who make broadly neutralizing antibodies.
Q52660832Neutralization Sensitivity of a Novel HIV-1 CRF01_AE Panel of Infectious Molecular Clones
Q37510242Neutralization Takes Precedence Over IgG or IgA Isotype-related Functions in Mucosal HIV-1 Antibody-mediated Protection
Q36223864New prospects for a preventive HIV-1 vaccine
Q34057711Nonneutralizing functional antibodies: a new "old" paradigm for HIV vaccines
Q33645528Novel directions in HIV-1 vaccines revealed from clinical trials
Q41144784Optimized Replicating Renilla Luciferase Reporter HIV-1 Utilizing Novel Internal Ribosome Entry Site Elements for Native Nef Expression and Function
Q40092127Potent and broad HIV-neutralizing antibodies in memory B cells and plasma
Q56970600Progress in HIV vaccine development
Q27693849Progress in HIV-1 vaccine development.
Q37621530Promise and problems associated with the use of recombinant AAV for the delivery of anti-HIV antibodies
Q38534943Prospects for a globally effective HIV-1 vaccine
Q44536209Safety, pharmacokinetics, and immunological activities of multiple intravenous or subcutaneous doses of an anti-HIV monoclonal antibody, VRC01, administered to HIV-uninfected adults: Results of a phase 1 randomized trial.
Q36294806Short Communication: Virion Aggregation by Neutralizing and Nonneutralizing Antibodies to the HIV-1 Envelope Glycoprotein
Q33813145Specificity and 6-month durability of immune responses induced by DNA and recombinant modified vaccinia Ankara vaccines expressing HIV-1 virus-like particles
Q42030724Spectrum of HIV antibodies in vaccine and disease
Q61816156Structural Basis for Epitopes in the gp120 Cluster A Region that Invokes Potent Effector Cell Activity
Q38243948The HIV-1 gp120 V1V2 loop: structure, function and importance for vaccine development
Q28830298Vaccine-Elicited Mucosal and Systemic Antibody Responses Are Associated with Reduced Simian Immunodeficiency Viremia in Infant Rhesus Macaques
Q33977866Vaccine-induced Env V1-V2 IgG3 correlates with lower HIV-1 infection risk and declines soon after vaccination
Q34059103Vaccine-induced HIV-1 envelope gp120 constant region 1-specific antibodies expose a CD4-inducible epitope and block the interaction of HIV-1 gp140 with galactosylceramide
Q34948847Vaccine-induced Human Antibodies Specific for the Third Variable Region of HIV-1 gp120 Impose Immune Pressure on Infecting Viruses
Q34402934Vaccine-induced IgG antibodies to V1V2 regions of multiple HIV-1 subtypes correlate with decreased risk of HIV-1 infection
Q93150656Vaccine-induced V1V2-specific antibodies control and or protect against infection with HIV, SIV and SHIV

Search more.